Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis

Henry J. Fuchs, Drucy S. Borowitz, David H. Christiansen, Edward M. Morris, Martha L. Nash, Bonnie W. Ramsey, Beryl J. Rosenstein, Beryl J Rosenstein, Mary Ellen Wohl

Research output: Contribution to journalArticle

Abstract

Background. Respiratory disease in patients with cystic fibrosis is characterized by airway obstruction caused by the accumulation of thick, purulent secretions, which results in recurrent, symptomatic exacerbations. The viscoelasticity of the secretions can be reduced in vitro by recombinant human deoxyribonuclease I (rhDNase), a bioengineered copy of the human enzyme. Methods. We performed a randomized, double-blind, placebo-controlled study to determine the effects of once-daily and twice-daily administration of rhDNase on exacerbations of respiratory symptoms requiring parenteral antibiotics and on pulmonary function. A total of 968 adults and children with cystic fibrosis were treated for 24 weeks as outpatients. Results. One or more exacerbations occurred in 27 percent of the patients given placebo, 22 percent of those treated with rhDNase once daily, and 19 percent of those treated with rhDNase twice daily. As compared with placebo, the administration of rhDNase once daily and twice daily reduced the age-adjusted risk of respiratory exacerbations by 28 percent (P = 0.04) and 37 percent (P

Original languageEnglish (US)
Pages (from-to)637-642
Number of pages6
JournalNew England Journal of Medicine
Volume331
Issue number10
DOIs
StatePublished - Sep 8 1994

Fingerprint

Cystic Fibrosis
Lung
Placebos
Airway Obstruction
Outpatients
dornase alfa
Anti-Bacterial Agents
Enzymes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. / Fuchs, Henry J.; Borowitz, Drucy S.; Christiansen, David H.; Morris, Edward M.; Nash, Martha L.; Ramsey, Bonnie W.; Rosenstein, Beryl J.; Rosenstein, Beryl J; Wohl, Mary Ellen.

In: New England Journal of Medicine, Vol. 331, No. 10, 08.09.1994, p. 637-642.

Research output: Contribution to journalArticle

Fuchs, Henry J. ; Borowitz, Drucy S. ; Christiansen, David H. ; Morris, Edward M. ; Nash, Martha L. ; Ramsey, Bonnie W. ; Rosenstein, Beryl J. ; Rosenstein, Beryl J ; Wohl, Mary Ellen. / Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. In: New England Journal of Medicine. 1994 ; Vol. 331, No. 10. pp. 637-642.
@article{c8a9384f60d4496980896de83867176a,
title = "Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis",
abstract = "Background. Respiratory disease in patients with cystic fibrosis is characterized by airway obstruction caused by the accumulation of thick, purulent secretions, which results in recurrent, symptomatic exacerbations. The viscoelasticity of the secretions can be reduced in vitro by recombinant human deoxyribonuclease I (rhDNase), a bioengineered copy of the human enzyme. Methods. We performed a randomized, double-blind, placebo-controlled study to determine the effects of once-daily and twice-daily administration of rhDNase on exacerbations of respiratory symptoms requiring parenteral antibiotics and on pulmonary function. A total of 968 adults and children with cystic fibrosis were treated for 24 weeks as outpatients. Results. One or more exacerbations occurred in 27 percent of the patients given placebo, 22 percent of those treated with rhDNase once daily, and 19 percent of those treated with rhDNase twice daily. As compared with placebo, the administration of rhDNase once daily and twice daily reduced the age-adjusted risk of respiratory exacerbations by 28 percent (P = 0.04) and 37 percent (P",
author = "Fuchs, {Henry J.} and Borowitz, {Drucy S.} and Christiansen, {David H.} and Morris, {Edward M.} and Nash, {Martha L.} and Ramsey, {Bonnie W.} and Rosenstein, {Beryl J.} and Rosenstein, {Beryl J} and Wohl, {Mary Ellen}",
year = "1994",
month = "9",
day = "8",
doi = "10.1056/NEJM199409083311003",
language = "English (US)",
volume = "331",
pages = "637--642",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "10",

}

TY - JOUR

T1 - Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis

AU - Fuchs, Henry J.

AU - Borowitz, Drucy S.

AU - Christiansen, David H.

AU - Morris, Edward M.

AU - Nash, Martha L.

AU - Ramsey, Bonnie W.

AU - Rosenstein, Beryl J.

AU - Rosenstein, Beryl J

AU - Wohl, Mary Ellen

PY - 1994/9/8

Y1 - 1994/9/8

N2 - Background. Respiratory disease in patients with cystic fibrosis is characterized by airway obstruction caused by the accumulation of thick, purulent secretions, which results in recurrent, symptomatic exacerbations. The viscoelasticity of the secretions can be reduced in vitro by recombinant human deoxyribonuclease I (rhDNase), a bioengineered copy of the human enzyme. Methods. We performed a randomized, double-blind, placebo-controlled study to determine the effects of once-daily and twice-daily administration of rhDNase on exacerbations of respiratory symptoms requiring parenteral antibiotics and on pulmonary function. A total of 968 adults and children with cystic fibrosis were treated for 24 weeks as outpatients. Results. One or more exacerbations occurred in 27 percent of the patients given placebo, 22 percent of those treated with rhDNase once daily, and 19 percent of those treated with rhDNase twice daily. As compared with placebo, the administration of rhDNase once daily and twice daily reduced the age-adjusted risk of respiratory exacerbations by 28 percent (P = 0.04) and 37 percent (P

AB - Background. Respiratory disease in patients with cystic fibrosis is characterized by airway obstruction caused by the accumulation of thick, purulent secretions, which results in recurrent, symptomatic exacerbations. The viscoelasticity of the secretions can be reduced in vitro by recombinant human deoxyribonuclease I (rhDNase), a bioengineered copy of the human enzyme. Methods. We performed a randomized, double-blind, placebo-controlled study to determine the effects of once-daily and twice-daily administration of rhDNase on exacerbations of respiratory symptoms requiring parenteral antibiotics and on pulmonary function. A total of 968 adults and children with cystic fibrosis were treated for 24 weeks as outpatients. Results. One or more exacerbations occurred in 27 percent of the patients given placebo, 22 percent of those treated with rhDNase once daily, and 19 percent of those treated with rhDNase twice daily. As compared with placebo, the administration of rhDNase once daily and twice daily reduced the age-adjusted risk of respiratory exacerbations by 28 percent (P = 0.04) and 37 percent (P

UR - http://www.scopus.com/inward/record.url?scp=0028129568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028129568&partnerID=8YFLogxK

U2 - 10.1056/NEJM199409083311003

DO - 10.1056/NEJM199409083311003

M3 - Article

C2 - 7503821

AN - SCOPUS:0028129568

VL - 331

SP - 637

EP - 642

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 10

ER -